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Introduction 
A connection between food and health has been known to exist since the dawn of history. However, the 
advent of modern science refined this concept to an understanding that our health depends upon 
obtaining certain nutrients in specific quantities. This heralded the concept that improper nutrition may 
directly lead to disease states and spawned dozens of professions and fields of research that focus on 
the relationship between nutrition and health. This in turn has led to an exponential growth in our 
understanding of human nutrition and to the creation of dietary recommendations such as the Institute 
of Medicine’s Dietary Reference Intakes (DRI’s). Recently, advances in genetic technologies such as the 
sequencing of the human genome have begun to revolutionize the field of nutrition and radically 
altering the direction of research. Hundreds of genetic variants that predispose individuals to common 
diseases have been identified and as research continues the number of known disease-predisposing 
polymorphisms will multiply. However, human health does not solely depend on our genes but also on 
our environment. Understanding how these two factors interact is paramount to disease prevention and 
our diet has been identified as one of the most important factors to interact with our genes.1 Hence the 
creation of a new field within nutrition, nutrigenetics.  
Nutrigenetics aims to understand how the genetic makeup of an individual coordinates their response to 
diet.2 Therefore, nutrigenetics considers the genetic polymorphisms of an individual and how these 
variations interact with disease risk and diet. As research progresses, nutrigenetics will produce 
information that will assist clinicians in identifying the optimal diet for a given individual, i.e., 
personalized nutrition. If these goals are to be realized the field of nutrition must move beyond 
epidemiological studies using genetically uncharacterized populations and incorporate more complex 
models that account for cellular and molecular biology coupled with biochemistry and genetics.3 
The burgeoning field of nutrigenetics  has already discovered dozens of “candidate gene variants” which 
may confer a heightened sensitivity to specific nutritional factors and are known to modulate disease 
risk.3-5 Some of these genes have functionally important variations that are highly prevalent in the 
population. Genetic variation within these genes may explain discrepancies in previous epidemiologic 
studies that sought to find interactions between disease risk and diet. These polymorphisms also have 
the potential to alter individual optimal nutrition based upon genotype and in time their 
characterization may become indispensable to the field of clinical nutrition and dietetics. 
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Given the enormous potential of nutrigenetics to redefine optimal nutrition and to create truly 
personalized nutrition, the field of dietetics must find a way to incorporate these advances into nutrition 
therapy. Commercial nutrigenetic testing is rapidly rising in popularity and decreasing in price.3 
However, these tests used by consumers on their own lack the credibility that validated genetic tools in 
the hands of licensed nutrition professionals such as registered dietitians (RDs) can provide. RDs may 
view commercial nutrigenetic tests as tools or as competitors depending upon point of view. However, if 
the use of genetic information is to be of practical value in clinical practice, dietitians must be familiar 
with genetic terminology and stay reasonably informed of current nutrigenetic research. Furthermore, 
dietitians who seek to utilize genetic testing in clinical practice must have a firm grasp upon the moral, 
ethical, and legal implications of inherent to genetic testing. 
This paper will examine the current research surrounding five “candidate gene variants” and discuss 
how particular polymorphisms in these genes may affect clinical nutrition therapy. To provide a context 
for this discussion the following case scenario was constructed: 
A woman comes to a private dietetic practice seeking help interpreting the results of a 
genetic test she took after seeing an advertisement online. She is particularly concerned 
about her risk of breast cancer. Her mother recently died of the disease and the results 
mention breast cancer risk. She would also like help losing a “few extra pounds” she has 
gained over the past several years. She is a healthy 35 year old female who is 177cm tall, 
weighs 82kg (BMI= 26.2), and who exercises moderately. Her genetic test results have 
revealed the following genetic polymorphisms: APOA2 -265 CC, DHFR -ND, MGMT -427 
AG, CAT -262 CT APOA2 -265 CC, DHFR -ND, MGMT -427 AG, XRCC1 -26304 CT, CAT -262 
CT. 
Review of genetic polymorphisms 
APOA2 -265CC 
The APOA2 gene is a member of the apolipoprotein multigene superfamily, which includes genes 
encoding soluble apolipoproteins such as APOA1 and APOA4.6 The gene encodes the high density 
apolipoprotein A-II (APOA2) which is the second most abundant component of high-density lipoprotein 
(HDL) particles. APOA2 has been shown to be a regulator of triglyceride metabolism through its 
modulation of lipoprotein lipase activity and the high-density lipoprotein proteome.7,8 It has also been 
shown to play a role in the regulation of postprandial metabolism, particularly metabolic response to 
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saturated fat intake.7,8 In animal models overexpression of APOA2 results in hypertriglyceridemia, 
obesity, and insulin resistance9,10; however, its exact role in humans remains controversial.11-14 
A specific APOA2 promoter variant, a T→C transition at position -265 (rs no. 5082), has been shown by 
two independent studies to be associated with a 30% drop in basal transcription activity.11,12 A 
relationship between this variant and obesity has been clearly demonstrated. In an initial study, Corella 
et al found individuals that were homozygous for the APOA2-265C allele (CC) had statistically higher 
body mass index (BMI) than did carriers of the T allele (TC or TT) (OR=1.70, 95% CI: 1.02-2.80, P = 
0.039).15 CC individuals were also found to have significantly higher total energy, total fat, and total 
protein intake than T allele carriers. This research was then expanded and further confirmed through 
replication of the gene–diet interaction in three separate US populations (including Whites and Puerto 
Ricans), an elderly Spanish population, and in Asian Indians living in Singapore.16,17 In these studies, the 
APOA2 m265 T→C genotype was consistently associated with increased BMI or obesity in the context of 
high saturated fat intake. Among the US populations, individuals with the CC genotype and saturated fat 
intake >22g/day had a statistically significant increase in BMI ranging from 4.3% to 7.9%. A meta-analysis 
pooling data from these populations found the high saturated fat group (>22g/day) showed a 
statistically higher OR of obesity for CC homozygotes (OR=1.84, 95% CI: 1.38- 2.47, P=.001). However, in 
the low–saturated fat group, no increased OR for obesity was found for CC homozygotes (OR=0.81; 95% 
CI: 0.59-1.11; P=.18). This gene-diet interaction was again confirmed in the Mediterranean and Asian 
populations. The prevalence of the CC genotype was 15% in the Mediterranean population, ranged from 
10.5% to 16.2% in the US populations, and was only 1.6% in the Asian population.17 
Much like the overall function of APOA2 the underlying mechanism of the relationship between APOA2 
and obesity remains elusive. Smith et al examined this relationship with particular focus on patterns of 
eating and ghrelin, a hormonal regulator of food intake, in a Mediterranean population.18 Homozygous 
(CC) individuals were found to be more likely to exhibit a behavior identified as an obstacle for weight 
loss (‘Do you skip meals’, OR=2.09, P=0.008) and less likely to exhibit the protective behavior of ‘Do you 
plan meals in advance’ (OR=0.64, P=0.034). A lower saturated fat diet was associated with lower ghrelin 
in CC carriers which could be theorized to be responsible for lower energy intake and BMI; however, the 
interaction between saturated fat and APOA2 genotype was only found to be marginally modulated by 
plasma ghrelin (P=0.056). 
Despite the fact that the mechanism for the association of APOA2 the gene with saturated fat intake and 
obesity remains unclear, this gene–nutrient interaction has been more extensively demonstrated than 
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any other locus. Given the increased risk of obesity associated with a high saturated fat diet among 
homozygous CC carriers, dietary recommendations for these individuals should emphasize avoidance of 
saturated fats. Homozygous individuals may benefit more from this diet restriction than others and 
given the possible connection to hormonal regulators of appetite may find weight loss through a low 
saturated fat diet easier to adhere to than other methods. Ultimately, the gene-diet interaction will 
need to be further elucidated through intervention studies; however, based on the available evidence 
high saturated fat diets are a particular health risk for APOA2 265C carriers. 
MGMT 427 A→G 
The MGMT gene produces the DNA adduct repair molecule O6-methylguanine DNA-methyltransferase 
(MGMT) and is the only known gene to play a critical role in the DNA direct reversal repair (DRR) 
pathway, a cellular defense against alkylating agents.19,20 Alkylating agents are ubiquitous and are 
produced from both endogenous sources (nitrosation of amines) and exogenously (cigarette smoke, fuel 
combustion products).21-23 MGMT repairs DNA adducts caused by alkylating agents via the irreversible 
transfer of a methyl adduct to its active site (Cys145 in human MGMT).24 It has the highest affinity for 
the potent mutagenic and cytotoxic O6-Methylguanine (O6MeG) which when left unrepaired can lead to 
cell cycle arrest, sister chromatid exchanges, chromosomal aberrations and apoptosis.25 MGMT can also 
repair a variety of other O6-alkyl lesions including ethyl, chloroethyl, pyridyloxobutyl butyl, benzyl 
adducts, and O4-methylthymine.26-32  
MGMT is epigenetically silenced in many human cancers and evidence has shown that MGMT plays a 
role in decreasing cancer susceptibility in humans.33-35 Several studies have examined the association 
between MGMT polymorphisms and risk of lung cancer, melanoma, and glioblastoma36-43 although the 
results have been inconsistent and there is little data on how these polymorphisms affect functionality. 
These inconsistencies could be explained through a gene-diet interaction present in certain 
polymorphisms in the MGMT gene. The single nucleotide polymorphisms (SNP), MGMT-427 A→G, codes 
for a non-conservative amino acid substitution (Ile143Val) which is located almost adjacent to the alkyl 
acceptor Cys145 in the active site of the MGMT.36 An association between fruit and vegetable 
consumption and reduced breast cancer risk has been demonstrated among women with at least one 
variant allele for codon 143. Shen et al used biospecimens from the Long Island Breast Cancer Study to 
examine how the relationship between several MGMT polymorphisms and breast cancer may interact 
with dietary antioxidants and cigarette smoking.44 The AG or GG genotype was found in 22.1% of breast 
cancer cases and 23.6% of control cases in the study population. While there was no main effect upon 
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risk of breast cancer found for any genotype, among women with at least one variant allele for codon 
143 (AG or GG genotype) who consumed ≥35 servings of fruits and vegetables per week a significant 
reduction in breast cancer risk was found. (OR=0.6, 95% CI=0.5–0.9, compared to <34 servings per week 
and AA genotype). The OR for the AG+GG group consuming <34 servings was 1.2 (95% CI: 0.9–1.5), 
which represents a 60% reduction in risk. Additionally, similar reductions in risk were observed for high 
dietary α-carotene (>267.8µg/day) and supplemental β-carotene (>3817.38µg/day) (OR=0.6, 95% CI: 
0.4–0.8 and OR=0.7, 95% CI: 0.5–1.0, respectively, as compared to AA genotype and low intake). The 
data also supported an additive interaction between the 143 G-allele combined with high intake of fruits 
and vegetables (ICR=-0.5; 95% CI: -0.9,-0.1), and high intake of dietary a-carotene (ICR=-0.6; 95% CI: -0.2, 
-1.1), however the additive interaction for β-carotene was not statistically significant (ICR= -0.1; 95% CI: -
0.5, 0.2). A significant inverse association between high intake of fruits and vegetables and 
postmenopausal breast cancer has been previously demonstrated45; however, this study demonstrates 
this protection is partially dependent upon MGMT 143 G-allele status. 
The gene-diet interaction between the MGMT-427 A→G polymorphism and breast cancer risk has yet to 
be confirmed in among separate populations and the exact mechanism of this interaction remains 
unclear. However, based on the evidence from a large population study, women who are MGMT 143 G-
allele carriers may significantly reduce their breast cancer risk by consuming ≥35 servings of fruits and 
vegetables per week, perhaps by as much as 60%.44 This risk reduction may be partially due to increased 
α-carotene, and perhaps increased β-carotene, in the diet. Given this, women with the MGMT 143 G 
allele should be encouraged to consume at least 5 servings of fruits and vegetables per day and to 
include at least one serving of yellow-orange and dark green vegetables to provide sufficient α-carotene 
and β-carotene. 
CAT -262 CT 
The CAT gene encodes the catalase enzyme (CAT), a primary protector of cells against the damaging 
effects of reactive oxygen species (ROS). CAT is located in the peroxisomes of nearly all cells and can 
reduce a variety of reactive species, especially the common ROS hydrogen peroxide. A C→T SNP at 
position 262 has been shown to reduce enzyme activity46 and has been found to be associated with 
increased breast cancer risk.47 Ahn et al studied women in the Long Island Breast Cancer Study Project 
and found the high-activity catalase CC genotype was associated with an overall 17% reduction in risk of 
breast cancer compared with having at least one variant T allele (OR=0.83, 95% CI: 0.69- 1.00). The CC 
genotype was found in 60.9% of cases and 64.3% of controls. The association was found to significantly 
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interact with vegetable and especially fruit consumption and was greater among women who did not 
use vitamin supplements. An increased reduction of 29% (OR=0.71, 95% CI: 0.54, 0.92) was found 
among women with the CC genotype and higher consumption of fruits (>10 servings/week), compared 
with those with at least one T allele (TC and TT combined) and lower fruit consumption levels. The OR 
for CC genotype with ≤10 servings per week was 0.87 (95%CI: 0.68-1.11) representing a 16% reduction in 
risk through diet. The effect of dietary vitamin C, vitamin E, and β-carotene was also examined. A 26% 
reduction in risk among women with CC genotypes and a higher consumption of dietary vitamin C 
(>133.7 mg/day), compared with those with at least one T allele and lower consumption was found 
(OR=0.74, 95% CI: 0.57, 0.97), a 17% lower risk than CC carriers with lower vitamin C intake. A similar 
reduction in risk of 19% was found for CC genotypes consuming >7.87 α-tocopherol equivalents per day; 
however, the association failed to reach significance (OR = 0.81; 95% CI: 0.61-1.08, compared to 1 or 
more T allele with lower intake). Surprisingly, when β-carotene was examined reduced risk from high 
consumption (>2,673 µg/day) was not only found in CC carriers but also among the combined TC and TT 
genotype groups. Furthermore, the reduction in risk was greatest among TC and TT carriers who 
consumed >3,152.48 µg of β-carotene per day from both dietary and supplement sources (OR = 0.66, 
95% CI: 0.49-0.89). This represents a substantial 34% reduction in risk compared to TC and TT carries 
with lower β-carotene intake. No other significant reduction of risk from total antioxidant intake beyond 
that conferred by dietary sources alone was found and the lowest risk observed was for women who 
were high fruit consumers (>10 servings/week), had CC genotypes, and who did not use supplements 
(OR = 0.59, 95% CI: 0.38, 0.89).47 
More recently, Li et al conducted a similar nested case–control study of postmenopausal women from 
the Cancer Prevention Study-II Nutrition Cohort.48 While similar trends were found, Li et al. did not 
observe a statistically significant decreased risk of breast cancer with the CAT CC genotype (OR=0.83, 
95% CI: 0.66–1.04). In addition, the interaction between vegetable and fruit intake and genotypes was 
only borderline significant, with CAT CC genotype being inversely associated with breast cancer risk only 
among women with higher consumption of fruits and vegetables. CC carriers were actually found to be 
at increased risk compared to heterozygous carriers when consuming low amounts of fruits and 
vegetables (OR=1.33, 95% CI: 0.89, 1.99). The relationships between breast cancer risk and genotypes 
was also assessed by low and high intakes of dietary vitamin C, vitamin E, and β-carotene, both from 
dietary and supplement sources. In all cases, associations with breast cancer risk were either not found 
or attenuated by vegetable and fruit intake. This study had a smaller sample size and included only 
postmenopausal women providing less power to detect any possible association however. 
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The gene-diet interaction between the CAT gene, breast cancer, and fruit and vegetable consumption 
remains unclear. As is the case with nearly all gene-diet associations, further research is warranted and 
the association must continue to be study in context of multiple populations. Based on the results of the 
study by Ahn et al. , the more common CAT 262 CC carriers may have an overall reduced risk of breast 
cancer. Both studies discussed indicate a trend toward a reduced risk of breast cancer for all women 
when consuming a diet high in fruits and vegetables. This effect may actually be highest among the 
lower risk CC carriers or stated simply, a way to make their good genes even better. For the less 
common heterozygous genotype women, a diet high in fruit and vegetables may be a way to mitigate a 
possible increased risk with the nutrient β-carotene being of particular importance. Based on the results 
of the Ahn et al study women with the CT or TT genotype may reduce their risk of breast cancer by 34% 
through obtaining >2,673 µg of β-carotene per day from diet and supplemental sources. In all other 
cases supplemental antioxidants were not found to confer any protective benefit beyond that of diet. 
Consequently, all women should be counseled to consume at least 5 servings of fruits and vegetables 
per day in the context of breast cancer risk reduction. Additionally, women with CT or TT genotype for 
the CAT gene should be strongly encouraged to eat at least one serving of dark green or yellow-orange 
vegetables per day. 
XRCC1 26304C→T 
The X-ray repair cross complementing group 1 (XRCC1) gene plays an important role in DNA base 
excision repair. This process is critical for the molecular repair of DNA damage caused by DNA adducts, 
single strand breaks, and replication errors. Without this process, oxidized lesions and non-bulky 
adducts may block DNA replication or cause cytotoxic mutations and genetic instability possibly leading 
to tumor formation.49 A common variant 26304C→T has been shown to cause a non-conservative amino 
acid substitution (Arg194Trp) and may affect protein structure and function.50,51 Although studies on 
how the variant may affect DNA repair have had mixed results, some epidemiologic studies have found 
the variant it is associated with reduced risk of many types of cancer including: bladder, breast, lung, 
and stomach cancer.52-54 Studies examining breast the association between the 26304C→T variant and 
cancer risk specifically however have failed to reach a consensus, with some studies showing risk 
reduction and some showing no association.55-66 
Using the Long Island Breast Cancer Study Project, Shen et al. examined the relationship between the 
XRCC1 -26304 C→T polymorphism; breast cancer susceptibility; and intake of fruits, vegetables, and 
antioxidants.67 No significant change in breast cancer risk was observed among carriers of 26304 C→T 
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variant as a whole; however in individuals with at least one copy of the 194Trp allele, there was a 
significant reduction in risk associated with high intake of fruits and vegetables (≥35 half-cup servings/ 
week) (OR=0.58; 95% CI: 0.38-0.89) as compared to individuals with the Arg194Arg genotype and low 
intake of these factors. This translates to a considerable 55% reduction in breast cancer risk among 
Arg/Trp and Trp/Trp women through dietary factors (OR=1.13, 95%CI: 0.83-1.55 for Arg/Trp and Trp/Trp 
with <35 servings/week). A reduction in risk was also found among individuals with at least one 194Trp 
allele with high intakes (dietary and supplemental) of Vit C (>131.1 mg/d) (OR= 0.63, 95% CI: 0.43-0.93) 
and Vit E (>29.1mg/day) (OR=0.65, 95% CI: 0.44-0.96). Corresponding to a 60% risk reduction for Vit C 
and a 57% risk reduction for Vit E (OR=1.23, 95%CI: 0.88-1.73; OR=1.22, 95% CI 0.88-1.70; for at least 1 
194Trp allele and lower Vit C and Vit E intake, respectively) After controlling for other sources of 
antioxidants (diet and supplemental), these associations remained essentially unchanged. For high β-
carotene (>3817.3µg/d) and α-carotene (>267.8µg/d), similar significant reductions were also reported; 
however, after adjustment for intake of fruits and vegetables, the ORs were no longer significant. The 
incidence of at least one 194Trp allele in the control group was 6.72% which is similar to other reported 
incidences (5-7%) from American and European Caucasian women.55,56,58 However, the frequency has 
been reported to be much higher (34%) among Asian women. 56,57 
A similar study was done by Patel et al. using the American Cancer Society Cancer Prevention Study II 
(CPS-II) Nutrition Cohort.68 Unlike the Shen et al. study, a significant reduction in breast cancer risk was 
found for Trp194 carriers (Trp/Trp and Trp/Arg) when compared with non-carriers (Arg/Arg) (OR=0.62, 
95% CI: 0.40-0.95). In this study, the association between XRCC1 polymorphisms and breast cancer risk 
was not found to significantly interact with fruit and vegetable intake. Although this study had a very 
large sample size, a significant limitation is that most participants were aged 50 to 74 years at 
enrollment. As was the case with evidence surrounding the CAT diet-gene interaction, this may decrease 
the ability of the study to detect gene-diet interactions caused earlier in life. The Shen et al. study did 
not report data based on menopausal or age status. 
Inconsistencies in the research regarding the XRCC1 26304C→T variant and its association with breast 
cancer as well as a possible gene-diet interaction continue to exist signaling the need for continued 
research and possible additions to the model. The gene-diet interaction found by Shen et al. was not 
reproduced in a subsequent study on a separate population; however, significant differences exist 
within the study populations. Based on the data from the study by Shen et al., women with at least one 
copy of the XRCC1 194Trp allele may reduce their risk of breast cancer by 55% by consuming at least 5 
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servings of fruits and vegetables per day. Additionally, the vitamins A and E appear to be of particular 
importance and 194Trp carriers may also reduce breast cancer risk by consuming >131.1 mg of vitamin C 
and >29.1 mg vitamin E per day from diet and supplemental sources combined. This level of vitamin C 
may be obtained through diet given at least 5 servings of fruits and vegetables per day, especially if a 
variety of colorful fruits and vegetables are eaten. However, obtaining >29.1mg of vitamin E (over twice 
the RDA) from dietary sources alone is difficult. As such, women with the 194Trp allele may benefit from 
vitamin E and perhaps vitamin C supplementation in the context of breast cancer risk reduction. 
DHFR ND 
The DHFR gene encodes the enzyme dihydrofolate reductase (DHFR) which plays an essential role in 
single-carbon metabolism by converting dihydrofolate (DHF) into the active tetrahydrofolate (THF) form. 
The reduction of folate to the THF form is required for DNA synthesis and is essential for cellular 
metabolism and growth.69 Dietary folate is absorbed predominantly in the fully reduced 5-methyl-THF 
form although other less reduced forms are also found. On the other hand, folate found in supplements 
is absorbed in the fully unreduced (e.g., folic acid) form and must be acted upon by DHFR to be 
metabolically active.70,71 The Food and Drug Administration began fortifying foods with folic acid in 
January of 1998 to prevent neural tube defects; however, folate has also been investigated for its 
potential anti-carcinogenic role in breast cancer. Several large epidemiologic studies have found that 
adequate folate intake reduces the risk of breast cancer72-74; however, results have been mixed75,76 and a 
recent study found folic acid supplementation of >400 µg/day was associated with a 20% increase in 
breast cancer risk in postmenopausal women.77 These conflicting results may be due in part to genetic 
polymorphisms in the DHFR gene that effect folate utilization from supplement use and in turn also play 
a role in breast cancer risk. 
A 19 base pair deletion (19-bp) polymorphism in intron 1 of the DHFR gene has been identified78 and 
found to be homozygous in about 1 in 5 Americans.79 The 19-bp allele may affect transcription factor 
binding and gene regulation thus affecting overall enzyme function.80 Xu et al. utilized the Long Island 
Breast Cancer Study Project to investigate the functionality of the polymorphism and its effect on breast 
cancer risk.80 The DHFR 19-bp allele was found in 40% and 42% of the cases and controls, respectively. 
Overall, the DHFR 19-bp deletion polymorphism was not significantly associated with breast cancer risk. 
However, examination of the association between the DHFR polymorphism and breast cancer by 
multivitamin (MVI) use revealed the 19-bp -/- genotype and multivitamin use was associated with a 52% 
increase in breast cancer risk (95% CI: 1.08, 2.13) compared with individuals with the +/+ genotype. This 
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association was dose-dependent and represented a 57% increase in risk associated with multivitamin 
use amongst individuals with the 19-bp -/- genotype (OR for non-MVI= 0.95, 95%CI: 0.66-1.36). The -/- 
genotype was found in 19.7% and 18.7% of controls, respectively. Approximately half (51.2%) of the 
study population used multivitamins on a regular basis (>1 time/wk) over the 10–15 year period before 
enrollment, however multivitamin use was not significantly associated with the risk of breast cancer 
overall (OR=0.95; 95% CI: 0.83-1.10). In contrast, no significant interaction between the DHFR 19-bp 
deletion polymorphism and dietary or total folate intake was found. Using a small sample, Xu et al the 
effect of the 19-bp genotype on DHFR functionality and found a significant dose-dependent relation (P 
for trend=0.001) between DHFR expression genotype. Compared with the 19-bp +/+ genotype, the +/- 
and -/- genotypes had a 2.4-fold and 4.8-fold increase in mRNA levels, respectively. The authors 
theorized the 19-bp segment may lie within an inhibitory element of the DHFR gene and on removal 
gene expression is up-regulated causing higher DHFR activity. This may lead to depletion of the 5,10-
methylene-THF pool and change the balance of single-carbon metabolism in favor of DNA synthesis at 
the expense of methyl supply. This could then lead to aberrant DNA methylation, which has been 
associated with breast carcinogenesis.81 
These findings support more recent data from the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial77 that indicated too much folic acid from supplements may be procarcinogenic and 
demonstrate a gene-diet interaction that may be partially responsible. Additional studies will need to be 
conducted to confirm the association in separate populations and to establish recommended levels of 
folic acid intake based on DHFR 19-bp genotype. However, based on the data from the Xu et al. study, 
multivitamins are detrimental to the health of 19-bp -/- women from the standpoint of breast cancer 
risk. Given the function of the DHFR gene, this may be due to folic acid content of multivitamins and as 
such 19-bp -/- women may decrease their risk of breast cancer from avoiding all supplements containing 
high levels of folic acid. The implication of folic acid fortification in food for this subset of women 
remains unclear; however, until further research is conducted women with the DHFR 19bp -/- genotype 
should avoid exceeding the RDA for folate (320 µg/day for non-pregnant women), especially from 
supplemental and fortified sources. 
Putting it all together 
With the exception of the APOA2 gene, the gene-diet interactions examined above have yet to be 
reproduced in multiple populations. As such, the interactions must be viewed as unconfirmed 
associations, especially when making clinical decisions. Even the APOA2 gene’s interaction with 
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saturated fat, which has been replicated in three separate populations, needs to be more closely 
examined in intervention studies. Given this, the expected benefit of following a low saturated fat diet 
or any diet recommendations based upon the gene-diet interactions examined remains unclear.  
However, this is not to suggest that the genotypic information obtained by the woman in the sample 
case is of no clinical utility. The large size of the risk reductions seen in the studies reviewed indicates an 
enormous potential for benefit through optimization of diet. Clinicians must assess the relative strength 
of the current evidence verses any potential harm a particular diet intervention may present. In most 
cases, the dietary intakes responsible for reduced risk in the gene-diet interactions examined are already 
in agreement with current dietary recommendations. For instance, eating at least 5 servings of fruits and 
vegetables per day is consistent with the USDA’s 2010 Dietary Guidelines for Americans’ message of 
making half your plate fruits and vegetables.82 A diet that limits saturated fat is also certainly congruent 
with the DRI of for saturated fat which simply advises individuals to consume an amount as low as 
possible while still maintaining a nutritionally adequate diet.83 In such cases where nutrigenetic 
optimization is in line with the current standard of care, clinicians may use nutrigenetic information as 
further evidence for the benefit of diet modification and as a way to personalize recommendations. In 
some cases nutrigenetic information will be able to provide more detailed recommendations on specific 
nutrients while still falling with the current standard of care. Whether these personalized and specific 
recommendations will translate into improved clinical outcomes is unknown. Clinicians still must find a 
way to translate dietary guidance into a form that is understandable and actionable for individuals. The 
benefits of nutrigenetic diet optimization are just as dependent on compliance as any other 
intervention. 
Nutrigenetic studies may also find that certain individuals benefit from dietary intakes that fall outside 
of current dietary guidelines. It is probable that these types of gene-diet interactions exist within the 
population; however, clinicians must be careful before implementing these recommendations in clinical 
practice. Until intervention studies are conducted the true outcome of any such intervention will remain 
unknown no matter how compelling the epidemiologic data. Multiple genes interact with any given 
nutrient and the human biological system remains too complex to accurately predict outcomes before 
clinical trials have been conducted. This represents a significant hurdle for the field of nutrigenetics to 
overcome due to the cost and difficulty of conducting long term diet modification intervention studies. 
Never the less, clinicians must seek to do no harm first and be wary of making dietary recommendations 
that have the potential to be detrimental. 
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Returning to the test case, based upon the research reviewed a number of dietary recommendations 
could be made. First, she may reduce her risk of obesity from following a low saturated fat diet 
(<22g/day) due to her APOA2 -265CC genotype. Given the possible connection of this gene-diet 
interaction to hormonal regulators of appetite, if her diet was previously high in saturated fat this diet 
modification may also help her to lose weight. Second, the data indicate she may significantly reduce 
her risk of breast cancer by consuming at least 5 servings of fruits and vegetables per day. Due to her 
MGMT 143 G allele and CAT -262 CT genotype, she could possibly further reduce her breast cancer risk if 
she included at least one serving of yellow-orange or dark green vegetables per day to provide sufficient 
α-carotene and β-carotene. The goal for β-carotene would be >2,673 µg/day. The DRIs’ estimated 
average requirement (EAR) for vitamin A is 500 µg of retinol activity equivalents (RAEs) per day which 
would translate to 6000 µg of β-carotene making this recommendation well within current guidelines.83 
Additionally, based upon her XRCC1 26304C→T polymorphism she may also reduce her breast cancer 
risk by consuming >131.1 mg of vitamin C and >29.1 mg vitamin E per day. This amount of vitamin C 
would be obtainable within the five daily fruits and vegetables, especially if a variety of colors was 
included. This level is above the EAR of 60 mg per day but well below the DRIs’ Tolerable Upper Intake 
Level (UL) of 2,000 mg. Similarly, 29.1 mg of vitamin E is above the EAR of 12mg per day; however, it is 
much lower than the UL of 1000mg.83,84 Unlike the recommended level of vitamin C however, this 
amount of vitamin E is not easily obtainable in the diet and may require supplementation. This 
represents another layer of complexity for the clinician and issues such as availability and cost verses 
benefit and risk must be considered. Finally, avoiding excess folic acid and especially folic acid containing 
supplements may decrease her risk of breast cancer based on the evidence surrounding the DFFR 19-bp 
-/- genotype. Given that the case is still of reproductive age, one must also consider the risk of neural 
tube defects however. A review of the client’s pregnancy risk could be the deciding factor in determining 
the most appropriate level of folate to recommend. Regardless, the client could be safely advised not to 
exceed the DRI of folic acid equivalents from dietary and supplemental sources combined (320 mg for 
non-pregnant women and 520 mg for pregnant women per day).82 
The expected benefit from adherence to the recommendations is difficult to predict given the lack of 
intervention studies. While high saturated fat diets are associated with obesity risk in APOA2 -265CC 
individuals, it remains unknown if low saturated fat diets will be effective at producing weight loss. 
Based on the evidence however, one could assume that the case’s risk of gaining weight and becoming 
obese would be significantly reduced (OR=1.84 vs OR=0.81) by consuming <22 g of saturated fat per day. 
The expected reduction in breast cancer risk is even more difficult to assess. The client has multiple 
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polymorphisms that interact with fruit and vegetable consumption and breast cancer risk. These 
polymorphisms may interact with each other to produce even greater reductions in risk than seen in the 
research reviewed. Given the significant reductions in the studies reviewed however (60% for MGMT 
427 A→G, 16% for CAT -262 CT, and 55% for XRCC1 26304C→T), a large benefit may be expected from 
diet modification if the client previously had low fruit and vegetable consumption. Increased fruit and 
vegetable consumption is known to have other health benefits as well, although epidemiologic data on 
the overall association between fruits and vegetables and breast cancer risk remain unclear.85 Finally, 
the research reviewed found a 57% increase in breast cancer risk associated with MVI use among 19-bp 
-/- genotype individuals. Given this, if the client regularly took a folic acid containing MVI, a significant 
reduction in risk could be expected from discontinuing its use. Again however, this is an assumption as 
intervention studies have not been conducted. The chance of a woman having invasive breast cancer 
some time during her life is a little less 1 in 8 and the chance of dying from breast cancer is about 1 in 
35.86 Although many of these dietary interventions may seem simple, the potential benefit is profound 
especially given the clients family history of breast cancer. 
Implementation 
As seen above, in many cases, nutrigenetic diet optimization will require individual nutrients to be 
obtained in specific quantities. This represents a significant challenge for clinicians to translate these 
types of recommendations into actionable and consumable advice. Tracking single nutrient intake 
requires analyzing all dietary intake through reference food databases. Adjusting intake to meet specific 
requirements would then require careful planning of intake each day. This is arduous and unrealistic for 
clinicians and incompatible with societal norms for clients so novel tools must be utilized to increase 
adherence with these types of nutrient recommendations. Computer programs that track intake could 
provide information directly back to the client about the dietary adequacy of any single nutrient and 
help to plan meals to better meet recommendations. These programs could be available online or even 
through smart phones although they would still require the user to input all dietary intake and to 
preplan meals. If clients could be persuaded to track and modify their intake using such programs for 
only a few weeks or even days, significant progress toward meeting nutrigenetic goals could be made. If 
these dietary changes could then be incorporated into a client’s normal dietary routine improvements in 
meeting specific nutrient requirements could be made without permanent tracking of dietary intake. To 
realize the full potential benefits of nutrigenetic diet optimization however, individuals would need to 
continue to use such programs on a daily basis to ensure nutrient requirements are met. Many 
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individuals may find this level of attention to diet incompatible with their lifestyle and outside of societal 
norms. This represents a significant challenge in implementing nutrigenetic diet optimization and 
realizing the goal of personalized nutrition. In this regard however, nutrigenetics is not alone. Creating 
meaningful behavior change given societal constraints is a crux for all who seek to prevent disease 
through behavior modification. The benefit of nutrigenetics however, is that the underlying guidelines 
upon which dietary modification are based would be personalized for each client’s genotype. In other 
words, nutrigenetics aims for a more accurate ideal. This may allow for clients to achieve greater benefit 
from proportionally equal behavior modification and improve clinical outcomes. 
Conclusion 
Recent advances in genetic technologies are in the process of reshaping our understanding of nutrition 
and have spawned the new field of nutrigenetics. The inclusion of genetic data in nutrition research 
enables the complex human biological system, which includes cellular biology and molecular biology as 
well as biochemistry and genetics, to be more accurately approximated. Nutrigenetics utilizes data 
about the genetic makeup of an individual to better understand their response to diet. As research 
advances, nutrigenetics may radically alter our understanding of what constitutes an optimal diet for a 
given individual and creates the possibility of personalized nutrition. Dozens of gene-diet interactions 
have already been found in large epidemiologic studies that radically alter disease risk based upon 
dietary factors. As such, nutrigenetics represents a powerful new tool for clinicians and nutrition 
professionals such as registered dietitians. 
However, if this tool is to be adeptly utilized, clinicians must expand their scope of knowledge to include 
an understanding of basic genetic concepts as well as the practical, ethical, and legal implications of 
obtaining and using genetic data for nutrition guidance. They must also stay abreast of current 
nutrigenetic research, especially given the rise of direct to consumer nutrigenetic testing that may be 
grounded more in sales than in science. This paper has examined the research surrounding five 
proposed gene-diet interactions and explored how genotypic data on these genes may affect clinical 
practice. While more research is needed to confirm these gene-diet interactions, based upon the 
evidence examined certain individuals may significantly reduce their risk of obesity and breast cancer 
through nutrigenetic diet optimization.  
In the future, nutrigenetic data may become indispensable to the field of clinical nutrition and dietetics; 
however, new systems that can translate specific nutrient targets into actionable and practical dietary 
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advice must be developed. The utility of nutrigenetics is in providing the best target to aim for. By 
improving the underlying dietary recommendations clinicians may be able to improve outcomes without 
requiring increased behavior change. It is also possible that individuals may be more apt to change their 
behavior if they receive recommendations that are based upon their unique genetic makeup. However, 
the challenge of changing dietary behavior to modulate disease risk will remain.  
While nutrigenetics is still in its early stages, significant and clinically relevant findings have already been 
made. Future research will undoubtedly increase our understanding of how our genes interact with our 
diet and provide a more accurate assessment of optimal diet for any given individual. This will provide 
an invaluable tool for nutrition professionals such as registered dietitians and has the potential to 
significantly improve clinical outcomes. 
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